As prefilled injection devices continue to replace vials in terms of doses as well as total sector revenue, pharmaceutical and biotech program managers are increasingly integrating syringe and self-injection device technology into their development plans. The result has been a migration toward multi-functional development teams and an increasing reliance on accelerated product feasibility testing. As the factors driving this trend continue to evolve over the next six years, the number of tailored injectable drug products that reach the market will escalate.
As an elegant and utilitarian form of injectable drug packaging, prefilled syringes represent a landmark success story of the convergence of device engineering and market requirements. Prefilled syringes continue to experience double-digit annual unit growth (slightly above twelve percent in 2011). Not unexpectedly, evolution in prefilled syringe device design and technology has led to the increasing availability of devices that provide incremental value to drug marketers with product margins that afford these higher cost devices.
Improved patient compliance, efficient delivery of high-priced biologicals, and patient & caregiver safety are key market drivers in this sector. The cost of biologicals such as recombinant proteins has created interest in prefilled syringes to reduce cost and waste associated with the handling of vial-packaged drugs. Partnerships between device designers and drug developers are an essential element in the success of prefilled devices, particularly for patient self-administration.
A new and comprehensive report on global prefilled syringe markets conducted by Greystone Research Associates has just been released. The report - Prefilled Syringes to 2018: Devices, Drugs, Markets, Players and Prospects - includes analysis and assessments of prefilled syringe devices, injectable drugs, and combination products, evaluations of therapeutic markets, an examination of market factors, and profiles of market participants.
Greystone Research Associates (greystoneassociates.org) is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.